EMEA-001625-PIP02-21
Key facts
| Invented name |
Enspryng
|
| Active substance |
satralizumab
|
| Therapeutic area |
Neurology
|
| Decision number |
P/0532/2021
|
| PIP number |
EMEA-001625-PIP02-21
|
| Pharmaceutical form(s) |
Solution for injection
|
| Condition(s) / indication(s) |
Treatment of myasthenia gravis
|
| Route(s) of administration |
Subcutaneous use
|
| Contact for public enquiries |
Roche Registration GmbH
E-mail: global.paediatrics@roche.com |
| Decision type |
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
|